These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 216884)

  • 1. Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins.
    Witztum JL; Schonfeld G; Weidman SW; Giese WE; Dillingham MA
    Metabolism; 1979 Mar; 28(3):221-9. PubMed ID: 216884
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.
    Kuo PT; Hayase K; Kostis JB; Moreyra AE
    Circulation; 1979 Feb; 59(2):199-211. PubMed ID: 215338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
    Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO
    Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric familial type II hyperlipoproteinemia: therapy with diet and colestipol resin.
    Glueck CJ; Fallat RW; Mellies M; Tsang RC
    Pediatrics; 1976 Jan; 57(1):68-74. PubMed ID: 174057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of colestipol therapy in Type II hyperlipoproteinemia.
    Lees AM; McCluskey MA; Lees RS
    Atherosclerosis; 1976; 24(1-2):129-40. PubMed ID: 182181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile acid sequestrants and hyperlipidaemia.
    Lancet; 1988 Jan; 1(8579):220-1. PubMed ID: 2893044
    [No Abstract]   [Full Text] [Related]  

  • 8. Colestipol in familial type II hyperlipoproteinemia: a three-year trial.
    Harvengt C; Desager JP
    Clin Pharmacol Ther; 1976 Sep; 20(3):310-4. PubMed ID: 182429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in plasma lipoprotein lipids in hypercholesterolaemic patients treated with the bile acid-sequestering resin, colestipol.
    Clifton-Bligh P; Miller NE; Nestel PJ
    Clin Sci Mol Med; 1974 Dec; 47(6):547-57. PubMed ID: 4375013
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of encapsulated, low-dose colestipol in patients with hyperlipidemia.
    Linet OI; Grzegorczyk CR; Demke DM
    J Clin Pharmacol; 1988 Sep; 28(9):804-6. PubMed ID: 3230147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia.
    Seplowitz AH; Smith FR; Berns L; Eder HA; Goodman DS
    Atherosclerosis; 1981 Apr; 39(1):35-43. PubMed ID: 7018502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hypercholesterolaemia with colestipol: a bile sequestrating agent.
    Nye ER; Jackson D; Hunter JD
    N Z Med J; 1972 Jul; 76(482):12-6. PubMed ID: 4344110
    [No Abstract]   [Full Text] [Related]  

  • 15. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
    Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
    Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertriglyceridemia: a relative contraindication to the use of bile acid-binding resins?
    Denke MA; Grundy SM
    Hepatology; 1988; 8(4):974-5. PubMed ID: 3391527
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of colestipol on the metabolism of very-low-density lipoproteins in man.
    Witztum JL; Schonfeld G; Weidman SW
    J Lab Clin Med; 1976 Dec; 88(6):1008-18. PubMed ID: 186544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type III hyperlipoproteinemia: rise in high-density lipoprotein levels in response to therapy.
    Falko JM; Witztum JL; Schonfeld G; Weidman SW; Kolar JB
    Am J Med; 1979 Feb; 66(2):303-10. PubMed ID: 218451
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.
    Crouse JR; Grundy SM
    Metabolism; 1981 Feb; 30(2):123-8. PubMed ID: 7464561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of probucol on lipoprotein protein kinetics.
    Nestel PJ
    Artery; 1982; 10(2):95-8. PubMed ID: 7092582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.